A-Alpha Bio

Executive Summary

A-Alpha Bio is a Seattle-based biotechnology company that combines synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions at scale. Its proprietary platforms, AlphaSeq and AlphaBind, enable high-throughput characterization of binding affinities and specificities, generating massive datasets that train predictive models for therapeutic antibody and molecular glue discovery. By addressing a critical bottleneck in drug development—the identification and optimization of protein interactions—the company offers a systematic, data-driven approach that can significantly accelerate preclinical timelines. A-Alpha Bio has formed partnerships with leading biopharmaceutical organizations to advance programs across oncology, immunology, and other disease areas, validating its technology in real-world drug discovery settings. The company’s platform-agnostic, scalable methodology positions it as a key enabler in the growing field of protein engineering, with potential applications beyond therapeutics, including diagnostics and industrial enzymes. Despite being privately held with limited public financial disclosures, A-Alpha Bio’s technological differentiation and partnership traction suggest strong potential for continued growth and impact in the biotech ecosystem.

Upcoming Catalysts (preview)

• TBDAnnouncement of new major pharma partnership leveraging AlphaSeq platform75% success
• Q3 2026Publication of validation data in peer-reviewed journal demonstrating platform accuracy60% success
• Q4 2026Series B or later-stage financing round to scale operations50% success